Back to Journals » OncoTargets and Therapy » Volume 9

BET inhibitors in the treatment of hematologic malignancies: current insights and future prospects

Authors Abedin S, Boddy C, Munshi H

Received 7 July 2016

Accepted for publication 25 August 2016

Published 28 September 2016 Volume 2016:9 Pages 5943—5953

DOI https://doi.org/10.2147/OTT.S100515

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 2

Editor who approved publication: Dr Yao Dai


Sameem M Abedin,1 Craig S Boddy,1 Hidayatullah G Munshi1–3

1Department of Medicine, Feinberg School of Medicine, Northwestern University, 2Medicine Service, Jesse Brown VA Medical Center, 3The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA

Abstract: The bromodomain and extra-terminal (BET) family of proteins are important epigenetic regulators involved in promoting gene expression of critical oncogenes. BET inhibitors have been demonstrated to repress c-Myc expression, and were initially shown to have efficacy in a number of c-Myc-dependent hematologic malignancies. Recent studies have now revealed a broader role for BET inhibitors in hematologic malignancies. In this review, we summarize the efficacy of BET inhibitors in preclinical models of acute leukemia, lymphoma, and multiple myeloma. We also summarize recent results of clinical trials utilizing BET inhibitors in hematologic malignancies, characterize potential resistance mechanisms to BET inhibitors, and discuss potential combination therapies with BET inhibitors in patients with hematologic malignancies.

Keywords: leukemia, lymphoma, multiple myeloma, toxicity, resistance mechanisms

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]